Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

Inclusion Criteria:

1. Have been enrolled and completed a sponsored-clinical study of EN3835 (for theEN3835-222 study, participants who completed the study are those that completed theDay 57 visit, were assessed for safety and received at least 1 dose of studyintervention).

2. Willing and able to comply with all protocol required visits and assessments.

3. Agree not to use opioids during the study period and has not used opioids 2 weeksprior to the Observational Day 1 Visit.

4. Agree to not initiate or change use of orthotics or inserts designed to relievesymptoms of plantar fibromatosis during the study period.

5. Willing and able to comply with all protocol required visits and assessments.

6. Be adequately informed and understand the nature and risks of the study and be ableto provide consent

7. If female, be of non-childbearing potential (history of hysterectomy, bilateraloophorectomy, bilateral tubal ligation, or postmenopausal with no history ofmenstrual flow in the 12 months prior to the Day 1 Visit), or, if of childbearingpotential, be nonpregnant, non-lactating and agree to use effective contraceptionwhen with a male partner for the duration of the study and for 28 days after anyactive treatment period.

8. Have no significant medical history or examination findings related to theparticipant's plantar nodules, which in the investigator's opinion, would make theparticipant unsuitable for EN3835 administration.

Exclusion Criteria:

1. Has any musculoskeletal, neuromuscular, neurosensory, or other neurological orrelated disorder that affects the participant's use of his or her feet and/or wouldimpair his/her completion of study assessments as determined by the investigator.

2. Any other significant medical condition or had an SAE in the parent study which inthe investigator's opinion, would make the participant unsuitable for enrollment inthe study.

3. Received or plans to receive surgical or non-surgical treatments on the foot ornodules that were treated.

4. Has a known systemic allergy to collagenase or any other excipient of EN3835.

5. Has a known bleeding disorder that would make the participant unsuitable fortreatment or retreatment in the study.

6. Has significant medical history or examination findings related to the participant'splantar nodules, which in the investigator's opinion, would make the participantunsuitable for EN3835 administration.

7. Has a known coagulation disorder or is taking any medications that would increasethe risk of bleeding (except <150mg of aspirin daily, 7 days prior to firstinjection and for the duration of the study.